Terufumi Kawamoto1,2, Keiji Nihei3, Keisuke Sasai4, Katsuyuki Karasawa3. 1. Division of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 18-22-3 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. t.kawamoto@cick.jp. 2. Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Tokyo, Japan. t.kawamoto@cick.jp. 3. Division of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 18-22-3 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. 4. Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Abstract
BACKGROUND: Palliative therapeutic strategies in esophageal squamous cell carcinoma (ESCC) patients with dysphagia remain controversial. Only few studies have assessed therapeutic effect factors related to improvement in dysphagia score and nutrition-support-free survival (NSFS). OBJECTIVE: The present study assessed the efficacy and therapeutic effect factors related to the use of palliative radiotherapy (RT) and chemoradiotherapy (CRT) in ESCC patients with dysphagia. METHODS: We retrospectively evaluated 70 patients with stage IVA/B ESCC. Patients received RT of 30 Gy in 10 fractions or concurrent CRT using 5-fluorouracil plus cisplatin of 40 Gy in 20 fractions. The change in the dysphagia score from before to after treatment was assessed, and NSFS was evaluated. RESULTS: The median follow-up duration was 6 months (range 1-41 months). The overall rate of improvement in the dysphagia score was 60%. The median NSFS was 7.5 months. Craniocaudal tumor length < 6 cm, tumor circumference < 3/4, and CRT of 40 Gy in 20 fractions were associated with a significant improvement in the dysphagia score (p = 0.0036, p = 0.0069, and p = 0.03, respectively). NSFS was significantly longer with CRT than with RT (p = 0.048). CONCLUSION: Palliative RT and CRT are effective treatment options for ESCC patients with dysphagia. Craniocaudal tumor length < 6 cm, tumor circumference < 3/4, and CRT of 40 Gy in 20 fractions may improve dysphagia. CRT of 40 Gy in 20 fractions may improve NSFS.
BACKGROUND: Palliative therapeutic strategies in esophageal squamous cell carcinoma (ESCC) patients with dysphagia remain controversial. Only few studies have assessed therapeutic effect factors related to improvement in dysphagia score and nutrition-support-free survival (NSFS). OBJECTIVE: The present study assessed the efficacy and therapeutic effect factors related to the use of palliative radiotherapy (RT) and chemoradiotherapy (CRT) in ESCCpatients with dysphagia. METHODS: We retrospectively evaluated 70 patients with stage IVA/B ESCC. Patients received RT of 30 Gy in 10 fractions or concurrent CRT using 5-fluorouracil plus cisplatin of 40 Gy in 20 fractions. The change in the dysphagia score from before to after treatment was assessed, and NSFS was evaluated. RESULTS: The median follow-up duration was 6 months (range 1-41 months). The overall rate of improvement in the dysphagia score was 60%. The median NSFS was 7.5 months. Craniocaudal tumor length < 6 cm, tumor circumference < 3/4, and CRT of 40 Gy in 20 fractions were associated with a significant improvement in the dysphagia score (p = 0.0036, p = 0.0069, and p = 0.03, respectively). NSFS was significantly longer with CRT than with RT (p = 0.048). CONCLUSION: Palliative RT and CRT are effective treatment options for ESCCpatients with dysphagia. Craniocaudal tumor length < 6 cm, tumor circumference < 3/4, and CRT of 40 Gy in 20 fractions may improve dysphagia. CRT of 40 Gy in 20 fractions may improve NSFS.
Authors: K Hayashi; N Ando; H Watanabe; H Ide; K Nagai; N Aoyama; W Takiyama; K Ishida; K Isono; H Makuuchi; M Imamura; M Shinoda; S Ikeuchi; T Kabuto; H Yamana; H Fukuda Journal: Jpn J Clin Oncol Date: 2001-09 Impact factor: 3.019
Authors: Z Kassam; R K S Wong; J Ringash; Y Ung; J Kamra; G DeBoer; M O'Brien; J Kim; D A Loblaw; S Wong; B Cummings; P Davey Journal: Clin Oncol (R Coll Radiol) Date: 2008-02 Impact factor: 4.126
Authors: J A Harvey; J R Bessell; E Beller; J Thomas; D C Gotley; B H Burmeister; E T Walpole; D B Thomson; I Martin; L Doyle; E Burmeister; B M Smithers Journal: Dis Esophagus Date: 2004 Impact factor: 3.429
Authors: Michael G Penniment; Paolo B De Ieso; Jennifer A Harvey; Sonya Stephens; Heather-Jane Au; Christopher J O'Callaghan; Andrew Kneebone; Samuel Y Ngan; Iain G Ward; Rajarshi Roy; Jennifer G Smith; Tirath Nijjar; James J Biagi; Liam A Mulroy; Rebecca Wong Journal: Lancet Gastroenterol Hepatol Date: 2017-12-14
Authors: S Lorenzen; T Schuster; R Porschen; S-E Al-Batran; R Hofheinz; P Thuss-Patience; M Moehler; P Grabowski; D Arnold; T Greten; L Müller; N Röthling; C Peschel; R Langer; F Lordick Journal: Ann Oncol Date: 2009-06-23 Impact factor: 32.976